Core Viewpoint - Valneva SE reported strong financial results for Q1 2025, with significant revenue growth and reduced operational cash burn, while confirming its financial guidance for the year [3][5][6]. Financial Performance - Total revenues for Q1 2025 were €49.2 million, a 50.3% increase from €32.8 million in Q1 2024 [5][6]. - Product sales reached €48.6 million, up 51.2% from €32.1 million in the same period last year [6][31]. - The company reported a net loss of €9.2 million compared to a net profit of €58.9 million in Q1 2024, which included €90.8 million from the sale of a Priority Review Voucher [6][45]. - Operating cash burn was reduced by 71% to €8.1 million in Q1 2025 from €28.4 million in Q1 2024 [6][47]. - Cash and cash equivalents stood at €153.0 million as of March 31, 2025, down from €168.3 million at the end of 2024 [6][50]. Product Sales and Market Developments - IXIARO®/JESPECT® sales increased by 65.5% to €27.5 million, driven by demand from travelers and the U.S. Department of Defense [10][32]. - DUKORAL® sales grew 9.4% to €12.3 million, supported by a supply agreement with the French government [12][33]. - IXCHIQ® sales surged to €3.0 million from €0.2 million in Q1 2024, with initial sales related to a chikungunya outbreak response [13][34]. - Third-party product sales increased to €5.8 million from €4.1 million, reflecting recovery from previous supply constraints [18][35]. Research and Development Highlights - Valneva is advancing its Lyme disease vaccine candidate, VLA15, with primary vaccinations completed and data expected by the end of 2025 [20][21]. - The company is also developing a tetravalent Shigella vaccine candidate, S4V2, with ongoing Phase 2 studies [23][24]. - A Phase 1 trial for a Zika vaccine candidate, VLA1601, is currently underway, with results anticipated this year [28][29]. Strategic Partnerships and Regulatory Progress - Valneva secured a $32.8 million supply contract for IXIARO® with the U.S. Department of Defense [7][11]. - The company received marketing authorization for IXCHIQ® in the UK and Brazil, marking significant milestones for its chikungunya vaccine [7][14][15]. - Valneva has entered into a licensing agreement with the Serum Institute of India to expand access to its chikungunya vaccine in Asia [15][61]. Financial Outlook - The company expects product sales to grow to €170-180 million in 2025, with total revenues projected to reach €180-190 million [6][5]. - R&D investments are anticipated to be between €90-100 million in 2025, partially offset by grant funding and tax credits [6][5].

Core Viewpoint - Integra LifeSciences Holdings Corporation is under investigation for potential securities fraud and unlawful business practices following disappointing financial results and significant stock price decline [1][2][3]. Financial Performance - For Q1 2025, Integra reported earnings per diluted share of -$0.33, a decline from -$0.04 per diluted share in the same period last year [2]. - The company provided full-year earnings guidance and a second-quarter revenue outlook that fell significantly short of consensus estimates [2]. - Declines were noted in the Neurosurgery and Tissue Technologies segments, attributed to inventory issues and slower ordering patterns [2]. Stock Market Reaction - Following the announcement of the financial results, Integra's stock price dropped by $3.57 per share, or 21.19%, closing at $13.28 per share on May 5, 2025 [3].

Company Overview - TOMI Environmental Solutions, Inc. specializes in disinfection and decontamination solutions, utilizing its proprietary Binary Ionization Technology (BIT) platform [4] - The BIT solution employs a low percentage of hydrogen peroxide as its active ingredient, utilizing patented ionized Hydrogen Peroxide (iHP) technology for superior disinfection [4] - TOMI's products are applicable in various environments, including hospitals, biosafety labs, pharmaceutical facilities, schools, and commercial buildings [4] Financial Reporting - TOMI will report its first-quarter results for the period ending March 31, 2025, after the market closes on May 8, 2025 [1] - A conference call to discuss these results will be held at 4:30 p.m. ET on the same day [1] Participation Information - Participants can join the conference call by dialing (877) 545-0320 or (973) 528-0002 for international callers, using access code 616069 [2] - A replay of the teleconference will be available until May 22, 2025, with access codes provided for both domestic and international callers [3]

Core Viewpoint - Sandstorm Gold Ltd. reported strong financial results for Q1 2025, driven by high commodity prices, with record revenues and net income, alongside ongoing share buybacks and deleveraging efforts [2][7][12]. Financial Highlights - Record revenue of $50.1 million, up from $42.8 million in Q1 2024 [7][12]. - Production of 18,492 attributable gold equivalent ounces, down from 20,316 ounces in the same period last year [7][12]. - Cash flows from operating activities of $40.8 million, compared to $32.6 million in Q1 2024 [7][15]. - Net income of $11.3 million, a significant improvement from a net loss of $3.9 million in Q1 2024 [7][15]. Shareholder Returns - The company repurchased approximately 3.1 million common shares for $19.1 million during Q1 2025, with an additional 270,000 shares purchased for $2.0 million post-quarter [2][3]. - Sandstorm renewed its normal course issuer bid (NCIB) allowing for the purchase of up to 20 million common shares, indicating a strategic focus on share repurchases [3]. Deleveraging Efforts - The company made $15 million in net debt repayments during the quarter, with an additional $12 million repaid after the quarter ended [4]. - As of May 6, 2025, Sandstorm has an outstanding balance of $328 million on its revolving credit facility, with an undrawn balance of $297 million [4]. Production and Revenue Breakdown - Approximately 73% of gold equivalent production was from precious metals, 20% from copper, and 7% from other commodities [12]. - Revenue from precious metals was $34.8 million, copper revenue was $11.3 million, and other commodities contributed $4.0 million [13]. Project Developments - The Hod Maden joint venture is advancing with approved early-works capital investments of $60–$100 million for 2025 [5]. - Glencore is expected to submit an application for the MARA copper-gold project under Argentina's RIGI, which aims to support large investments [6][8]. Production Outlook - Attributable gold equivalent ounces are forecasted to be between 65,000 and 80,000 ounces in 2025, with long-term production expected to reach approximately 150,000 ounces by 2030 [11].

ROCKVILLE, MD, May 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2025 after the market closes on Tuesday, May 13, 2025.  The Company will not be hosting a conference call to discuss its financial results or corporate progress for the quar ...

MARKHAM, Ontario, May 06, 2025 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) today announced its financial results for the three months ended March 31, 2025. Q1 2025 Highlights Average Same Property Occupancy in retirement segment up 260 basis points (“bps”) year-over-year to 92.5% in Q1 2025Total Adjusted Revenue, excluding One-Time Items increased by 12.1% in Q1 2025, to $241.8 millionTotal Adjusted Same Property Net Operating Income (“NOI”), excluding One-Time Items ...

Group 1 - Hudson Global, Inc. will release its first quarter financial results for the period ended March 31, 2025, before the market opens on May 13, 2025 [1] - A conference call to discuss the financial results will take place on the same day at 10:00 am ET [1] - The call will be accessible via dial-in and a simultaneous webcast on the company's investor relations website [1] Group 2 - Hudson Global, Inc. operates as a leading global total talent solutions provider under the brand name Hudson RPO [2] - The company offers customized recruitment outsourcing and total talent solutions to organizations worldwide [2] - Hudson Global focuses on developing tailored talent solutions to align with clients' strategic growth initiatives [2]

Core Insights - BioAtla, Inc. reported its financial results for Q1 2025, highlighting advancements in its Conditionally Active Biologic (CAB) platform and ongoing clinical trials for cancer therapies [1][8]. Financial Performance - Research and development (R&D) expenses for Q1 2025 were $12.4 million, down from $18.9 million in Q1 2024, primarily due to reduced clinical development costs [8]. - General and administrative (G&A) expenses decreased to $5.3 million in Q1 2025 from $5.6 million in Q1 2024 [9]. - The net loss for Q1 2025 was $15.3 million, compared to a net loss of $23.2 million in the same quarter of 2024 [9]. - Cash and cash equivalents as of March 31, 2025, were $32.4 million, down from $49.0 million at the end of 2024, with expectations to fund operations through key clinical readouts in 1H 2026 [11]. Clinical Developments - The Phase 1 dose-escalation study for CAB-EpCAM x CAB-CD3 (BA3182) is ongoing, with the first three patients dosed at 300 micrograms, and data readout expected in mid-2025 [5][6]. - Mecbotamab vedotin (Mec-V) demonstrated a 2-year landmark survival rate of 59% in mKRAS non-small cell lung cancer (NSCLC) patients, significantly higher than the less than 20% survival rate reported for standard care [5][6]. - Ozuriftamab vedotin (Oz-V) continues to show promising results in HPV-positive squamous cell carcinoma of the head and neck, with a disease control rate of 100% and an overall response rate of 45% [6][5]. Strategic Initiatives - The company is utilizing Fast Track Designation from the FDA for discussions regarding a proposed Phase 3 study for Oz-V in treatment-refractory metastatic HPV-positive SCCHN [13]. - BioAtla is focusing on its two internal priority programs and expects cost reductions from its recent restructuring [11]. Upcoming Events - Management will host a conference call and webcast on May 6, 2025, to discuss the financial results and clinical updates [12]. - BioAtla has presentations scheduled at major oncology conferences, including the ASCO Annual Meeting and ESMO Gastrointestinal Cancers Congress [13].

SuRo Capital Portfolio Investment, CoreWeave, Completes Largest Tech IPO Since 2021 SuRo Capital Portfolio Investment, OpenAI, Closes Largest Venture Raise with $300 Billion Valuation Net Asset Value of $6.66 Per Share as of March 31, 2025 NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- SuRo Capital Corp. (“SuRo Capital”, the “Company”, “we”, “us”, and “our”) (Nasdaq: SSSS) today announced its financial results for the first quarter ended March 31, 2025. Net assets totaled approximately $156.8 million, or $6.66 ...

NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Carlyle Secured Lending, Inc. (together with its consolidated subsidiaries, “we,” “us,” “our,” “CGBD” or the “Company”) (NASDAQ: CGBD) today announced its financial results for its first quarter ended March 31, 2025. Justin Plouffe, CGBD’s Chief Executive Officer, said, “Following successful completion of the merger with CSL III at the end of March, CGBD remains focused on driving stable income, consistent credit performance, and disciplined execution of our strate ...